Loading…

GENE-30. TRANSCRIPTION ELONGATION FACTORS REPRESENT IN VIVO CANCER DEPENDENCIES IN GLIOBLASTOMA

Glioblastoma is a universally lethal cancer with a median survival of approximately 15 months. Despite substantial efforts to define druggable targets, there are no therapeutic options that meaningfully extend glioblastoma patient lifespan. While previous work has largely focused on in vitro cellula...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2017-11, Vol.19 (suppl_6), p.vi99-vi99
Main Authors: Miller, Tyler E, Liau, Brian, Wallace, Lisa C, Morton, Andrew, Xie, Qi, Dixit, Deobrat, Factor, Daniel, Kim, Leo, Morrow, James, Wu, Qiulian, Mack, Stephen, Hubert, Christopher, Paddison, Patrick J, Horbinski, Craig, Bernstein, Bradley, Tesar, Paul, Rich, Jeremy
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1884-836da7df1859385b16ea500e62cc157b789e5817fec64560b4edf885ac19e6993
cites
container_end_page vi99
container_issue suppl_6
container_start_page vi99
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 19
creator Miller, Tyler E
Liau, Brian
Wallace, Lisa C
Morton, Andrew
Xie, Qi
Dixit, Deobrat
Factor, Daniel
Kim, Leo
Morrow, James
Wu, Qiulian
Mack, Stephen
Hubert, Christopher
Paddison, Patrick J
Horbinski, Craig
Bernstein, Bradley
Tesar, Paul
Rich, Jeremy
description Glioblastoma is a universally lethal cancer with a median survival of approximately 15 months. Despite substantial efforts to define druggable targets, there are no therapeutic options that meaningfully extend glioblastoma patient lifespan. While previous work has largely focused on in vitro cellular models, here we demonstrate a more physiologically relevant approach to target discovery in glioblastoma. We adapted pooled RNA interference (RNAi) screening technology for use in orthotopic patient-derived xenograft (PDX) models, creating a high-throughput negative selection screening platform in a functional in vivo tumour microenvironment. Using this approach, we performed parallel in vivo and in vitro screens and discovered that the chromatin and transcriptional regulators necessary for cell survival in vivo are non-overlapping with those required in vitro. We identified transcription pause-release and elongation factors as one set of in vivo-specific cancer dependencies and determined that these factors are necessary for enhancer-mediated transcriptional adaptations that enable cells to survive the tumour microenvironment. Our lead hit, JMJD6, mediates the upregulation of in vivo stress and stimulus response pathways through enhancer-mediated transcriptional pause-release, promoting cell survival specifically in vivo. Targeting JMJD6 or other identified elongation factors extends survival in orthotopic xenograft mouse models, supporting targeting the transcription elongation machinery as a therapeutic strategy for glioblastoma. More broadly, this study demonstrates the power of in vivo phenotypic screening to identify new classes of ‘cancer dependencies’ not identified by previous in vitro approaches, which could supply untapped opportunities for therapeutic intervention.
doi_str_mv 10.1093/neuonc/nox168.404
format article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5692366</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_5692366</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1884-836da7df1859385b16ea500e62cc157b789e5817fec64560b4edf885ac19e6993</originalsourceid><addsrcrecordid>eNpVkNFOgzAYhRujiXP6AN7xAmz9KS3lxgRZhyRYFsDdNlCKzmywgDP69m7DmHh1TnJyvosPoXvAM8A-mbfm0LV63nZfwPjMxe4FmgB1iE05Y5fn7ticgneNbobhHWMHKIMJUpGQwiZ4ZhVZIPMwi1dFnEpLJKmMgnNdBmGRZrmViVUmciELK5bWOl6nVhjIUGTWQqyEXAgZxiI_bVESp49JkBfpc3CLrppyO5i735yil6Uowic7SaM4DBJbA-euzQmrS69ugFOfcFoBMyXF2DBHa6Be5XHfUA5eYzRzKcOVa-qGc1pq8A3zfTJFDyN3f6h2ptam_ejLrdr3m13Zf6uu3Kj_S7t5U6_dp6LMdwhjRwCMAN13w9Cb5u8LWJ0Uq1GxGhWro2LyA6h8az8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>GENE-30. TRANSCRIPTION ELONGATION FACTORS REPRESENT IN VIVO CANCER DEPENDENCIES IN GLIOBLASTOMA</title><source>Oxford Journals Online</source><source>PubMed Central</source><creator>Miller, Tyler E ; Liau, Brian ; Wallace, Lisa C ; Morton, Andrew ; Xie, Qi ; Dixit, Deobrat ; Factor, Daniel ; Kim, Leo ; Morrow, James ; Wu, Qiulian ; Mack, Stephen ; Hubert, Christopher ; Paddison, Patrick J ; Horbinski, Craig ; Bernstein, Bradley ; Tesar, Paul ; Rich, Jeremy</creator><creatorcontrib>Miller, Tyler E ; Liau, Brian ; Wallace, Lisa C ; Morton, Andrew ; Xie, Qi ; Dixit, Deobrat ; Factor, Daniel ; Kim, Leo ; Morrow, James ; Wu, Qiulian ; Mack, Stephen ; Hubert, Christopher ; Paddison, Patrick J ; Horbinski, Craig ; Bernstein, Bradley ; Tesar, Paul ; Rich, Jeremy</creatorcontrib><description>Glioblastoma is a universally lethal cancer with a median survival of approximately 15 months. Despite substantial efforts to define druggable targets, there are no therapeutic options that meaningfully extend glioblastoma patient lifespan. While previous work has largely focused on in vitro cellular models, here we demonstrate a more physiologically relevant approach to target discovery in glioblastoma. We adapted pooled RNA interference (RNAi) screening technology for use in orthotopic patient-derived xenograft (PDX) models, creating a high-throughput negative selection screening platform in a functional in vivo tumour microenvironment. Using this approach, we performed parallel in vivo and in vitro screens and discovered that the chromatin and transcriptional regulators necessary for cell survival in vivo are non-overlapping with those required in vitro. We identified transcription pause-release and elongation factors as one set of in vivo-specific cancer dependencies and determined that these factors are necessary for enhancer-mediated transcriptional adaptations that enable cells to survive the tumour microenvironment. Our lead hit, JMJD6, mediates the upregulation of in vivo stress and stimulus response pathways through enhancer-mediated transcriptional pause-release, promoting cell survival specifically in vivo. Targeting JMJD6 or other identified elongation factors extends survival in orthotopic xenograft mouse models, supporting targeting the transcription elongation machinery as a therapeutic strategy for glioblastoma. More broadly, this study demonstrates the power of in vivo phenotypic screening to identify new classes of ‘cancer dependencies’ not identified by previous in vitro approaches, which could supply untapped opportunities for therapeutic intervention.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/nox168.404</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Abstracts</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi99-vi99</ispartof><rights>The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1884-836da7df1859385b16ea500e62cc157b789e5817fec64560b4edf885ac19e6993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5692366/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5692366/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Miller, Tyler E</creatorcontrib><creatorcontrib>Liau, Brian</creatorcontrib><creatorcontrib>Wallace, Lisa C</creatorcontrib><creatorcontrib>Morton, Andrew</creatorcontrib><creatorcontrib>Xie, Qi</creatorcontrib><creatorcontrib>Dixit, Deobrat</creatorcontrib><creatorcontrib>Factor, Daniel</creatorcontrib><creatorcontrib>Kim, Leo</creatorcontrib><creatorcontrib>Morrow, James</creatorcontrib><creatorcontrib>Wu, Qiulian</creatorcontrib><creatorcontrib>Mack, Stephen</creatorcontrib><creatorcontrib>Hubert, Christopher</creatorcontrib><creatorcontrib>Paddison, Patrick J</creatorcontrib><creatorcontrib>Horbinski, Craig</creatorcontrib><creatorcontrib>Bernstein, Bradley</creatorcontrib><creatorcontrib>Tesar, Paul</creatorcontrib><creatorcontrib>Rich, Jeremy</creatorcontrib><title>GENE-30. TRANSCRIPTION ELONGATION FACTORS REPRESENT IN VIVO CANCER DEPENDENCIES IN GLIOBLASTOMA</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Glioblastoma is a universally lethal cancer with a median survival of approximately 15 months. Despite substantial efforts to define druggable targets, there are no therapeutic options that meaningfully extend glioblastoma patient lifespan. While previous work has largely focused on in vitro cellular models, here we demonstrate a more physiologically relevant approach to target discovery in glioblastoma. We adapted pooled RNA interference (RNAi) screening technology for use in orthotopic patient-derived xenograft (PDX) models, creating a high-throughput negative selection screening platform in a functional in vivo tumour microenvironment. Using this approach, we performed parallel in vivo and in vitro screens and discovered that the chromatin and transcriptional regulators necessary for cell survival in vivo are non-overlapping with those required in vitro. We identified transcription pause-release and elongation factors as one set of in vivo-specific cancer dependencies and determined that these factors are necessary for enhancer-mediated transcriptional adaptations that enable cells to survive the tumour microenvironment. Our lead hit, JMJD6, mediates the upregulation of in vivo stress and stimulus response pathways through enhancer-mediated transcriptional pause-release, promoting cell survival specifically in vivo. Targeting JMJD6 or other identified elongation factors extends survival in orthotopic xenograft mouse models, supporting targeting the transcription elongation machinery as a therapeutic strategy for glioblastoma. More broadly, this study demonstrates the power of in vivo phenotypic screening to identify new classes of ‘cancer dependencies’ not identified by previous in vitro approaches, which could supply untapped opportunities for therapeutic intervention.</description><subject>Abstracts</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkNFOgzAYhRujiXP6AN7xAmz9KS3lxgRZhyRYFsDdNlCKzmywgDP69m7DmHh1TnJyvosPoXvAM8A-mbfm0LV63nZfwPjMxe4FmgB1iE05Y5fn7ticgneNbobhHWMHKIMJUpGQwiZ4ZhVZIPMwi1dFnEpLJKmMgnNdBmGRZrmViVUmciELK5bWOl6nVhjIUGTWQqyEXAgZxiI_bVESp49JkBfpc3CLrppyO5i735yil6Uowic7SaM4DBJbA-euzQmrS69ugFOfcFoBMyXF2DBHa6Be5XHfUA5eYzRzKcOVa-qGc1pq8A3zfTJFDyN3f6h2ptam_ejLrdr3m13Zf6uu3Kj_S7t5U6_dp6LMdwhjRwCMAN13w9Cb5u8LWJ0Uq1GxGhWro2LyA6h8az8</recordid><startdate>20171106</startdate><enddate>20171106</enddate><creator>Miller, Tyler E</creator><creator>Liau, Brian</creator><creator>Wallace, Lisa C</creator><creator>Morton, Andrew</creator><creator>Xie, Qi</creator><creator>Dixit, Deobrat</creator><creator>Factor, Daniel</creator><creator>Kim, Leo</creator><creator>Morrow, James</creator><creator>Wu, Qiulian</creator><creator>Mack, Stephen</creator><creator>Hubert, Christopher</creator><creator>Paddison, Patrick J</creator><creator>Horbinski, Craig</creator><creator>Bernstein, Bradley</creator><creator>Tesar, Paul</creator><creator>Rich, Jeremy</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20171106</creationdate><title>GENE-30. TRANSCRIPTION ELONGATION FACTORS REPRESENT IN VIVO CANCER DEPENDENCIES IN GLIOBLASTOMA</title><author>Miller, Tyler E ; Liau, Brian ; Wallace, Lisa C ; Morton, Andrew ; Xie, Qi ; Dixit, Deobrat ; Factor, Daniel ; Kim, Leo ; Morrow, James ; Wu, Qiulian ; Mack, Stephen ; Hubert, Christopher ; Paddison, Patrick J ; Horbinski, Craig ; Bernstein, Bradley ; Tesar, Paul ; Rich, Jeremy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1884-836da7df1859385b16ea500e62cc157b789e5817fec64560b4edf885ac19e6993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, Tyler E</creatorcontrib><creatorcontrib>Liau, Brian</creatorcontrib><creatorcontrib>Wallace, Lisa C</creatorcontrib><creatorcontrib>Morton, Andrew</creatorcontrib><creatorcontrib>Xie, Qi</creatorcontrib><creatorcontrib>Dixit, Deobrat</creatorcontrib><creatorcontrib>Factor, Daniel</creatorcontrib><creatorcontrib>Kim, Leo</creatorcontrib><creatorcontrib>Morrow, James</creatorcontrib><creatorcontrib>Wu, Qiulian</creatorcontrib><creatorcontrib>Mack, Stephen</creatorcontrib><creatorcontrib>Hubert, Christopher</creatorcontrib><creatorcontrib>Paddison, Patrick J</creatorcontrib><creatorcontrib>Horbinski, Craig</creatorcontrib><creatorcontrib>Bernstein, Bradley</creatorcontrib><creatorcontrib>Tesar, Paul</creatorcontrib><creatorcontrib>Rich, Jeremy</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, Tyler E</au><au>Liau, Brian</au><au>Wallace, Lisa C</au><au>Morton, Andrew</au><au>Xie, Qi</au><au>Dixit, Deobrat</au><au>Factor, Daniel</au><au>Kim, Leo</au><au>Morrow, James</au><au>Wu, Qiulian</au><au>Mack, Stephen</au><au>Hubert, Christopher</au><au>Paddison, Patrick J</au><au>Horbinski, Craig</au><au>Bernstein, Bradley</au><au>Tesar, Paul</au><au>Rich, Jeremy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GENE-30. TRANSCRIPTION ELONGATION FACTORS REPRESENT IN VIVO CANCER DEPENDENCIES IN GLIOBLASTOMA</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2017-11-06</date><risdate>2017</risdate><volume>19</volume><issue>suppl_6</issue><spage>vi99</spage><epage>vi99</epage><pages>vi99-vi99</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Glioblastoma is a universally lethal cancer with a median survival of approximately 15 months. Despite substantial efforts to define druggable targets, there are no therapeutic options that meaningfully extend glioblastoma patient lifespan. While previous work has largely focused on in vitro cellular models, here we demonstrate a more physiologically relevant approach to target discovery in glioblastoma. We adapted pooled RNA interference (RNAi) screening technology for use in orthotopic patient-derived xenograft (PDX) models, creating a high-throughput negative selection screening platform in a functional in vivo tumour microenvironment. Using this approach, we performed parallel in vivo and in vitro screens and discovered that the chromatin and transcriptional regulators necessary for cell survival in vivo are non-overlapping with those required in vitro. We identified transcription pause-release and elongation factors as one set of in vivo-specific cancer dependencies and determined that these factors are necessary for enhancer-mediated transcriptional adaptations that enable cells to survive the tumour microenvironment. Our lead hit, JMJD6, mediates the upregulation of in vivo stress and stimulus response pathways through enhancer-mediated transcriptional pause-release, promoting cell survival specifically in vivo. Targeting JMJD6 or other identified elongation factors extends survival in orthotopic xenograft mouse models, supporting targeting the transcription elongation machinery as a therapeutic strategy for glioblastoma. More broadly, this study demonstrates the power of in vivo phenotypic screening to identify new classes of ‘cancer dependencies’ not identified by previous in vitro approaches, which could supply untapped opportunities for therapeutic intervention.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/nox168.404</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi99-vi99
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5692366
source Oxford Journals Online; PubMed Central
subjects Abstracts
title GENE-30. TRANSCRIPTION ELONGATION FACTORS REPRESENT IN VIVO CANCER DEPENDENCIES IN GLIOBLASTOMA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A28%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GENE-30.%20TRANSCRIPTION%20ELONGATION%20FACTORS%20REPRESENT%20IN%20VIVO%20CANCER%20DEPENDENCIES%20IN%20GLIOBLASTOMA&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Miller,%20Tyler%20E&rft.date=2017-11-06&rft.volume=19&rft.issue=suppl_6&rft.spage=vi99&rft.epage=vi99&rft.pages=vi99-vi99&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/nox168.404&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_5692366%3C/pubmedcentral_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1884-836da7df1859385b16ea500e62cc157b789e5817fec64560b4edf885ac19e6993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true